DCM
AST

Delpha Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Delpha Capital Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-115
Closed – – 1726
2017
Q4 		$0 Buy
+115
New +$291 ﹤0.01% 1693

Other funds holding AST

BC
Broadwood Capital New York $1.91B AUM 44.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Delpha Capital Management's AST Position: Q1 2018 in Review

Delpha Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2018, closing a stake of 115 shares.

Delpha Capital Management first reported a position in AST in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 72 funds tracked by Wall St. Rank hold AST as of Q1 2018.

  • Delpha Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 115 Asterias Biotherapeutics Inc. Series A shares in Q1 2018.
  • Delpha Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.